MTOR and cancer: Targeting those proteins led to the development of cancer therapeutics such as erlotinib and gefitinib (EGFR inhibitors), LY294002 (PI3K inhibitor), peritosine (Akt inhibitor), rapamycin and sirolimus (mTOR inhibitors), and many others.